Search

Displaying results 4821 - 4830 of 5897 in total
  1. Drug

    Muplestim

    go.drugbank.com/drugs/DB12431
    Investigational

    Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL

  2. Drug

    Azemiglitazone

    go.drugbank.com/drugs/DB16028
    Investigational

    Azemiglitazone is under investigation in clinical trial NCT01280695 (A Randomized, Double-blind, Comparator- and Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability and Efficacy

  3. Drug

    BMN-351

    go.drugbank.com/drugs/DB18186
    Investigational

    BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA.

  4. Drug

    Zosurabalpin

    go.drugbank.com/drugs/DB21539
    Investigational

    Zosurabalpin is under investigation in clinical trial NCT05614895 (A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections).

  5. Drug

    Sodium sulfide

    go.drugbank.com/drugs/DB11159
    Approved

    Interestingly, sodium sulfide was shown to have some cardioprotective role against cardiac ischemia or reperfusion injury, as well as protect lungs against ventilator-induced lung injury [A27275].

  6. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Results published from the CLL clinical trial failed to meet primary endpoints.

  7. Drug

    Trodusquemine

    go.drugbank.com/drugs/DB06333
    Investigational

    It has demonstrated the ability to stimulate regeneration of heart and multiple other tissues in animal models [A176600].

  8. Drug

    AAV-AIPL

    go.drugbank.com/drugs/DB17857
    Experimental

    Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.

  9. Drug

    Elsibucol

    go.drugbank.com/drugs/DB05840
    Experimental

    AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common

  10. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    It was last known to be in phase III clinical trials.